NDAORALTABLET, EXTENDED RELEASE
Approved
Dec 2016
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
IRA Negotiated
SYNJARDY XR (empagliflozin, metformin hydrochloride) by Boehringer Ingelheim is sodium-glucose transporter 2 inhibitors [moa]. Approved for sodium-glucose cotransporter 2 inhibitor [epc]. First approved in 2016.
Drug data last refreshed 2h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYNJARDY XR is a fixed-dose combination of empagliflozin (SGLT2 inhibitor) and metformin HCl (extended-release) for type 2 diabetes management. It works by inhibiting sodium-glucose cotransporter 2 to increase urinary glucose excretion while metformin reduces hepatic glucose production. This combination targets patients requiring dual therapy for improved glycemic control.
$278MPart D
PeakStable
8.1 years to LOEProduct is at peak revenue maturity with moderate claims volume; commercial teams should focus on managed care optimization and defensive positioning against IRA price reductions.
Mechanism of Action
Sodium-Glucose Transporter 2 Inhibitors
Pharmacologic Class:
Sodium-Glucose Cotransporter 2 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
$278M Medicare spend — this is a commercially significant brand
Worked on SYNJARDY XR at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.